Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics

Citi added an “upside 90-day catalyst watch” on shares of Travere Therapeutics (TVTX) while keeping a Buy rating on the name with a $48 price target The firm expects Filspari to receive FDA approval for focal segmental glomerulosclerosis on or before the action date of April 13. Citi believes the shares are not pricing in Travere’s opportunity in focal segmental glomeruloscleros.